Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1984 1
1985 1
1992 1
1994 3
1995 1
1997 1
2000 1
2001 3
2003 4
2004 6
2005 4
2006 4
2007 5
2008 3
2009 5
2010 8
2011 11
2012 25
2013 24
2014 34
2015 21
2016 36
2017 22
2018 16
2019 11
2020 17
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 24289844

248 results
Results by year
Filters applied: . Clear all
Page 1
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
Pozzilli C. Pozzilli C. Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Expert Rev Neurother. 2013. PMID: 24289844 Review.
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Flachenecker P. Flachenecker P. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Expert Rev Neurother. 2013. PMID: 23369055 Review.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P. Vermersch P. Expert Rev Neurother. 2011 Apr;11(4 Suppl):15-9. doi: 10.1586/ern.11.27. Expert Rev Neurother. 2011. PMID: 21449855 Review.
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
García-Merino A. García-Merino A. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Expert Rev Neurother. 2013. PMID: 23369054 Review.
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J, Vila C, Clissold S, Montalban X. Sastre-Garriga J, et al. Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Expert Rev Neurother. 2011. PMID: 21456949 Review.
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C. Oreja-Guevara C. Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Expert Rev Neurother. 2012. PMID: 22509985 Review.
Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
Koehler J, Amato MP, Oreja-Guevara C, Lycke J. Koehler J, et al. Expert Rev Neurother. 2013 Dec;13(12 Suppl):61-6. doi: 10.1586/14737175.2013.865881. Expert Rev Neurother. 2013. PMID: 24289846 Review.
Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O. Fernández O. Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26. Eur Neurol. 2014. PMID: 25278117 Free article.
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
Gold R, Oreja-Guevara C. Gold R, et al. Expert Rev Neurother. 2013 Dec;13(12 Suppl):55-9. doi: 10.1586/14737175.2013.865880. Expert Rev Neurother. 2013. PMID: 24289845 Review.
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P, Trojano M. Vermersch P, et al. Eur Neurol. 2016;76(5-6):216-226. doi: 10.1159/000449413. Epub 2016 Oct 13. Eur Neurol. 2016. PMID: 27732980
248 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback